About Us: Academic Founders

Graphite Bio Academic Founder Matthew Porteus M.D., Ph.D

Matthew Porteus, M.D., Ph.D.

Dr. Matthew Porteus’ visionary gene editing research led to the formation of Graphite Bio and our mission to develop best-in-disease therapies for patients with serious genetic disorders. Professor of Pediatrics and Stem Cell Transplantation and the Co-Director of Center for Definitive and Curative Medicine at Stanford University, Dr. Porteus is considered to be one of the scientific pioneers and founders of the field of genome editing. At his renowned Stanford Lab, he was first to demonstrate that gene correction could be achieved in human cells at frequencies that were high enough to potentially cure patients. His research is now the gold standard in gene editing, blazing the trail for medical innovation in a field that holds bold promise for addressing the underlying causes of diseases in order to save lives. In addition to his role as a scientific advisor, Dr. Porteus is a member of Graphite Bio’s Board of Directors.

Graphite Bio Academic Founder Maria Grazia Roncarolo M.D., Ph.D

Maria Grazia Roncarolo, M.D.

Dr. Roncarolo is one of the world’s foremost experts in gene therapy and one of Graphite Bio’s academic founders. She is recognized globally for her leadership in translating scientific discoveries in genetic diseases and regenerative medicine into novel patient therapies, including the world’s first ex vivo gene therapy. The George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine at Stanford University, Dr. Roncarolo established the Stanford Center for Definitive and Curative Medicine to cure patients with currently incurable diseases through the development of innovative stem cell and gene-based therapies. During her earlier tenure as director of the Telethon Institute for Gene Therapy at the San Raffaele Scientific Institute in Milan, Dr. Roncarolo developed novel approaches in gene therapy. Her work at the Institute led to the discovery of ex vivo gene therapies for genetic diseases of the immune system, including ADA-SCID and WASP, and metabolic diseases such as metachromatic leukodystrophy. The landmark stem cell gene therapy treatment for ADA-SCID was the world’s first to be approved by the European Medicines Agency (EMA) under the brand name Strimvelis® in May 2016.<

Graphite Bio Academic Founder Daniel Dever, Ph.D

Daniel Dever, Ph.D.

Dr. Daniel Dever is a co-founder and the head of discovery research at Graphite Bio. As a post-doctoral scholar working in the laboratory of Dr. Matthew Porteus at Stanford, Dr. Dever demonstrated an increase in site-specific DNA integration efficiency from less than 1% to greater than 50% across diverse genetic lesions in a wide range of cell types, including hard-to-edit hematopoietic stem cells. This work forms the foundation of our next-generation, high-efficiency DNA targeted integration platform. Dr. Dever’s research has published in an array of peer-reviewed journals including Nature, Cell Stem Cell, Molecular Therapy, Nature Medicine, Nature Protocols, Nucleic Acids Research and other high-impact journals.